|
|
 |
|
Viewing report
|
|
|
|
R&D Trends: Women's Health - Investment needed to address lack of innovation
Datamonitor, Dec 2011, Pages: 100
Investment into the women’s health sector has suffered in recent years as the pharmaceutical industry moves toward more profitable therapy areas. Nevertheless, the pipeline for new therapeutics remains active in women’s health with developments across a broad range of conditions at both the preclinical and clinical level. This report aims to identify and discuss some of these R&D trends.
Features and benefits
- Understand key dynamics in the R&D pipeline for new women’s health therapies
- Assess to what extent innovation exists in drug R&D for hormonal contraception, menopausal symptoms, uterine fibroids, endometriosis, and infertility.
- Support R&D decision making by evaluating clinical trial designs in key indications
- Access The prediction of how the treatment landscape may change in the next 20 years
Highlights
- There are 136 products in development for women’s health conditions. The highest proportions are for contraceptives and menopausal symptoms, which are the most established women’s health therapy areas, yet present growing barriers to entry.
- Uterine fibroids and endometriosis are attractive markets, yet there is limited investment and innovation. In the short term, the most eagerly awaited candidates are oral gonadotropin releasing hormone antagonists, while long term innovation is shown in diagnostic and biomarker research.
- Drug discovery investment is lacking in women’s health because of the lower perceived return. As such, patient access, not drug advances, will drive long term growth in the market. A continuous increase in the treatable population will be driven by raising demand for treatments, particularly for infertility and contraceptives.
Your key questions answered
- Which are the most targeted women’s health disorders by drug developers and why?
- What modes of action and administration are being targeted and by which companies im each of the core women’s health conditions?
- What is the most appropriate comparator therapy and what are the target product profiles for key women’s health indications?
- What are the requirements of European and US regulatory bodies to ensure approval of a novel candidate?
- How will the management of women’s health develop over the next 20 years?
|
|
|
|
